{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-25-000048","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.428504+00:00","generated_at":"2026-05-21T16:34:47.069730+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Krystal Biotech presents preclinical data for KB111 (HHD) and KB112 (Darier) at SID 2025","bullets":["KB111 targets ATP2C1 for Hailey-Hailey disease; KB112 targets ATP2A2 for Darier disease.","Both HSV-1-based vectors transduced keratinocytes with dose-dependent target protein expression and no cytotoxicity.","KB111 functionally corrected ATP2C1 siRNA knockdown in keratinocytes, reversing F-actin loss (p<0.05).","Topical administration in mice showed proper localization of ATP2C1 and ATP2A2 with minimal toxicity."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-25-000048","json":"https://secwatch.observer/filing/0001711279-25-000048.json","markdown":"https://secwatch.observer/filing/0001711279-25-000048.md","text":"https://secwatch.observer/filing/0001711279-25-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000048/0001711279-25-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000048/krys-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:34:47.069730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}